Evommune, Inc. (EVMN)
6.81
+0.50
(+7.92%)
USD |
NYSE |
Oct 29, 16:00
6.70
-0.11
(-1.62%)
After-Hours: 20:00
Evommune Enterprise Value : 54.92M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 54.92M |
| October 28, 2026 | 36.77M |
| October 27, 2026 | -4.950M |
| October 26, 2026 | -6.038M |
| October 23, 2026 | -7.127M |
| October 22, 2026 | -3.136M |
| October 21, 2026 | -4.587M |
| October 20, 2026 | 3.032M |
| October 19, 2026 | -0.9589M |
| October 16, 2026 | -4.587M |
| October 15, 2026 | 22.99M |
| October 14, 2026 | 17.18M |
| October 13, 2026 | 21.17M |
| October 12, 2026 | 27.34M |
| October 09, 2026 | 34.60M |
| October 08, 2026 | 40.40M |
| October 07, 2026 | 33.51M |
| October 06, 2026 | 47.66M |
| October 05, 2026 | 49.11M |
| October 02, 2026 | 58.91M |
| October 01, 2026 | 69.43M |
| September 30, 2026 | 107.52M |
| September 29, 2026 | 110.79M |
| September 28, 2026 | 112.24M |
| September 25, 2026 | 115.87M |
| Date | Value |
|---|---|
| September 24, 2026 | 127.12M |
| September 23, 2026 | 126.03M |
| September 22, 2026 | 156.14M |
| September 21, 2026 | 150.70M |
| September 18, 2026 | 157.96M |
| September 17, 2026 | 147.80M |
| September 16, 2026 | 147.80M |
| September 15, 2026 | 170.29M |
| September 14, 2026 | 186.26M |
| September 11, 2026 | 190.25M |
| September 10, 2026 | 190.97M |
| September 09, 2026 | 201.13M |
| September 08, 2026 | 282.40M |
| September 04, 2026 | 253.01M |
| September 03, 2026 | 243.22M |
| September 02, 2026 | 260.63M |
| September 01, 2026 | 260.63M |
| August 31, 2026 | 267.16M |
| August 28, 2026 | 287.84M |
| August 27, 2026 | 296.91M |
| August 26, 2026 | 319.77M |
| August 25, 2026 | 308.16M |
| August 24, 2026 | 303.81M |
| August 21, 2026 | 316.51M |
| August 20, 2026 | 300.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.312B |
| Oncolytics Biotech, Inc. | 49.64M |
| Sangamo Therapeutics, Inc. | 41.42M |
| Sarepta Therapeutics, Inc. | 2.288B |
| Anixa Biosciences, Inc. | 99.17M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.25M |
| Total Expenses (Quarterly) | 32.25M |
| EPS Diluted (Quarterly) | -0.8924 |
| Earnings Yield | -41.54% |
| Normalized Earnings Yield | -41.54 |